Uma Borate, Acute Leukemia Translation Lead, Assistant Professor at OHSU (Oregon Health and Science University), shared Joshua Zeidner’s post on X, adding:
“Our Blood Cancer Utd Beat AML Master Trial analysis providing benchmarks for outcomes in older NPM1 and KMT2A mutated AML pts as FL menin inhibitor studies are ongoing. Thanks to Joshua Zeidner and Jayanshu Jain for the collaboration with Beat AML PIs and team!”
Quoting Joshua Zeidner, Associate Professor of Medicine at the University of North Carolina at Chapel Hill, on X:
“Hot off the press – New Blood Cancer Utd Beat AML Analysis Blood Advances
analyzing clinical outcomes of NPM1m or KMT2Ar AML in pts >60 y/o. This is an important historical reference prior to use of Menin inhibitors.”
Title: Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML Report
Authors: Joshua F Zeidner, Jayanshu Jain, Rina Li Welkie, Ying Huang, Ronan Swords, Elie Traer, Eytan M. Stein, Tara L. Lin, Yazan F. Madanat, Robert H. Collins, Jr., Maria R Baer, Vu H. Duong, William Blum, Martha L. Arellano, Wendy A Stock, Olatoyosi Odenike, Rebecca L. Olin, Catherine C. Smith, James M. Foran, Gary J. Schiller, Emily Curran, Shivani Handa, Nyla A. Heerema, Timothy L Chen, Molly Martycz, Mona Stefanos, Sonja Marcus, Leonard Rosenberg, Brian J. Druker, Ross L Levine, Amy Burd, Ashley O Yocum, Alice S. Mims, John C. Byrd, Uma M Borate.
Other articles featuring Uma Borate and Joshua Zeidner